LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

Home・Список акций・Johnson and Johnson

Johnson and Johnson

Открыт

СекторЗдравоохранение

234.57 1.33

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

234.25

Макс.

235.09

Ключевые показатели
By Trading Economics
Доход	119M 5.2B
Продажи	-502M 24B
P/E Средняя по отрасли	26.526 49.701
Прибыль на акцию	2.7
Дивидендная доходность	2.29
Рентабельность продаж	21.756
Сотрудники	138,200
EBITDA	182M 6.4B

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+13.68% upside

Дивиденды
By Dow Jones
Дивидендная доходность Средняя по отрасли	2.29% 2.39%
Следующий отчет о доходах	15 июл. 2026 г.
Дата следующей выплаты дивидендов	9 июн. 2026 г.
Следующая эксдивидендная дата	26 мая 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-22B 551B
Предыдущая цена открытия	233.24
Предыдущая цена закрытия	234.57

Новостные настроения

By Acuity

20%

80%

25 / 345 Рейтинг в Healthcare

Johnson and Johnson График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 апр. 2026 г., 13:27 UTC

Приобретения, слияния, поглощения

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23 апр. 2026 г., 21:48 UTC

Приобретения, слияния, поглощения

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22 апр. 2026 г., 11:27 UTC

Отчет

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14 апр. 2026 г., 19:38 UTC

Отчет

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 апр. 2026 г., 14:13 UTC

Отчет

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 апр. 2026 г., 12:57 UTC

Отчет

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 апр. 2026 г., 11:19 UTC

Отчет

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 апр. 2026 г., 10:34 UTC

Отчет

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14 апр. 2026 г., 10:20 UTC

Обсуждения рынка

Отчет

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14 апр. 2026 г., 10:20 UTC

Обсуждения рынка

Отчет

J&J's Tremfya Sales Continue to Surge -- Market Talk

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14 апр. 2026 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Сравнение c конкурентами

Изменение цены

Johnson and Johnson Прогноз

Целевая цена

By TipRanks

13.68% рост

Прогноз на 12 месяцев

Средняя 266.4 USD 13.68%

Максимум 285 USD

Минимум 250 USD

Основано на мнении 17 аналитиков Wall Street, спрогнозировавших целевые цены для Johnson and Johnson на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

17 ratings

Покупка

Удержание

Продажа

Основано на мнении 17 аналитиков, присваивавших рейтинги акциям Johnson and Johnson – Данные за последние 3 месяца.

Настроения

By Acuity

25 / 345Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.